NCT05103358
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: TSC
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Other, Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 12 Years and older (Child, Adult, Older Adult))
Location of Metastases:
Additional Notes: Patients must have tumors that express a TSC1 or TSC2 alteration
Exclusions: Patients with prior treatment of an mTOR inhibitor, including nab-sirolimus; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05103358